US home › Compounded GLP-1s
Compounded GLP-1 products: our policy
About this page. Written by the GLPInfo editorial team with AI assistance from the official sources listed at the end, and approved by the site owner before publication. It has not been reviewed by a named clinician. Published 7 Sep 2026 · next scheduled review 7 Dec 2026.
This page is information, not medical advice. It never tells you which medicine or dose is right for you: those decisions sit with you and a licensed prescriber. Report suspected side effects to FDA MedWatch. Spotted an error? Tell us.
Many US telehealth channels sell compounded semaglutide, tirzepatide and now orforglipron at $31 to $349 a month, and most US comparison sites rank them as the cheapest options. GLPInfo's US edition does not list or rank compounded products. Here is why, in the FDA's own terms.
What the FDA says
Compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness or quality before they are marketed, and they are not generic versions of approved medicines. The FDA has stated that once a shortage of the approved drug has ended, compounders may not produce copies of it, and that a lower price is not a valid reason to compound. In 2025 and 2026 the FDA issued warning letters to telehealth companies over the marketing of compounded GLP-1 products, including some that presented them as equivalent to approved drugs.
What that means for a price comparison
A price comparison implies the things compared are comparable. A compounded product from one 503A pharmacy is not the same product as one from another, let alone the same as an FDA-approved medicine, and the sourcing, testing and labelling of each is not something a comparison site can verify from a web page. Ranking them by price would present as interchangeable things that are not, which is the exact framing the FDA has objected to. So GLPInfo's US edition compares FDA-approved products only.
Which channels are affected
Channels that sell only compounded GLP-1 products are not listed at all: Noom Med, Found, Henry Meds, Eden, Ivim Health, Orderly Meds, Fella Health / Delta, Zealthy, Emerge Weight Loss, Curex, Joi. Channels that sell both brand and compounded products (for example Mochi Health) are listed for their brand products only, with a note on their profile. Two of the compounded-only channels received FDA warning letters in June 2026.
If you are considering a compounded product anyway
Ask which pharmacy compounds it and whether it is a 503A or 503B facility, ask for the certificate of analysis, and check the FDA's compounding pages and warning-letter database. Discuss it with a licensed clinician who is not selling it. GLPInfo may add a clearly separated, non-ranked compounded section in a later release if independent verification becomes possible; it will never mix compounded and approved products in one ranking.
Frequently asked questions
Are compounded GLP-1s illegal?
Not inherently: compounding is lawful for patients whose needs cannot be met by an approved product, within FDA rules. What the FDA has acted against is mass production of copies of approved drugs after shortages ended, and marketing that presents compounded products as equivalent to approved ones.
Why do other comparison sites rank them?
Because they are the cheapest options and the highest-paying affiliate programs. GLPInfo's US edition earns no commissions, so there is no pull toward listing them.
Will GLPInfo ever list them?
Possibly as a separated, non-ranked section with the compounder named on every row, and only after legal review. Never in the same ranking as approved products.